Different azithromycin protocols for management of preterm prelabour rupture of membranes: a randomized clinical trial

Laila Ezzat Abdelfattah, Rehab Abdelhamid Aboshama, Amr S Abdelbadie, Mohamed H Abulhasan, Mohamed A Anan, Ibraheem I Abdelaal, Laila Ezzat Abdelfattah, Rehab Abdelhamid Aboshama, Amr S Abdelbadie, Mohamed H Abulhasan, Mohamed A Anan, Ibraheem I Abdelaal

Abstract

Background: Preterm prelabor rupture of membranes is associated with polymicrobial infection; hence broad-spectrum antibiotics are recommended. Nowadays, Azithromycin is used instead of Erythromycin due to erythromycin shortages, its ease of administration, decreased cost, and better side effect profile. This study aimed to evaluate the efficacy of different azithromycin protocols for the conservative management of preterm prelabor rupture of membranes.

Methods: It was a single-blinded randomized clinical trial including pregnant women at 24-36+6 weeks with viable singleton pregnancies and confirmed preterm prelabor rupture of membranes from January 01, 2020, to June 01, 2021. The participants were randomized into two groups: Group I was made of women who received Azithromycin 1000 mg PO once, and Group II of women who received Azithromycin 500 mg PO once, followed by Azithromycin 250 mg PO daily for four days. The primary study outcome was the length of the latency period from the diagnosis of preterm prelabor rupture of membranes to delivery (days).

Results: The latency period in group I was significantly higher than that in Group II (5.80 ± 5.44 days vs. 2.88 ± 2.37; respectively, p = 0.0001). The mean gestational age at the time of delivery was significantly higher in Group I (p = 0.0001). However, postpartum endometritis and respiratory distress syndrome (RDS) rates were significantly higher in Group II (p = 0.003 and p = 0.0001, respectively).

Conclusion: The higher dose of Azithromycin was associated with better maternal and neonatal outcomes.

Trial registration: Clinical trial identification number: Clinical trial.gov: NCT04202380 (17/ 12/ 2019). Date of registration: 1/1 /2020. Date of initial participant enrollment30 /1/2020. URL of the registration site: https://www.

Clinicaltrials: gov/ct2/show/NCT04202380.

Keywords: Azithromycin; Chorioamnionitis; Latency period; Neonatal outcomes; Preterm Pre-labor Rupture of Membranes.

Conflict of interest statement

The authors declare no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Patients' flow chart

References

    1. ACOG Committee on Practice Bulletins-Obstetrics ACOG Practice Bulletin No. 80. premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol. 2007;109:1007–1019. doi: 10.1097/01.AOG.0000263888.69178.1f.
    1. Mercer BM. Preterm premature rupture of the membranes. Obstet Gynecol. 2003;101:178–193.
    1. Thomson AJ. On behalf of the Royal College of Obstetricians and Gynaecologists. Care of women presenting with suspected preterm prelabour rupture of membranes from 24+0 weeks of gestation. BJOG. 2019;126:e152–e166. doi: 10.1111/1471-0528.15803.
    1. National Institute for Health and Care Excellence. Preterm labour and birth NG25; 2015. . Accessed 15 May 2017.
    1. Kenyon SL, Boulvain M, Neilson J. Antibiotic treatment in premature rupture of membranes: a systematic review. Obstet Gynecol. 2004;104:1051–1057. doi: 10.1097/01.AOG.0000143268.36682.21.
    1. Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstet Gynecol Clin North Am. 2005;32:411–428. doi: 10.1016/j.ogc.2005.03.003.
    1. Pierson RC, Gordon SS, Haas DM. Retrospective comparison of antibiotic regimens for preterm premature rupture of membranes. Obstet Gynecol. 2014;124:515–519. doi: 10.1097/AOG.0000000000000426.
    1. Finneran MM, Appiagyei A, Templin M, Mertz H. Comparison of Azithromycin versus Erythromycin for prolongation of latency in pregnancies complicated by preterm premature rupture of membranes. Am J Perinatol. 2017;34:1102–1107. doi: 10.1055/s-0037-1603915.
    1. Romero R, Chaemsaithong P, Korzeniewski SJ, Kusanovic JP, Docheva N, Martinez-Varea A, Ahmed AI, Yoon BH, Hassan SS, Chaiworapongsa T, Yeo L. Clinical chorioamnionitis at term III: how well do clinical criteria perform in the identification of proven intra-amniotic infection? J Perinat Med. 2016;44(1):23–32. doi: 10.1515/jpm-2015-0044.PMID:25918914;PMCID:PMC5881919.
    1. Bond DM, Middleton P, Levett KM, et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks gestation for improving pregnancy outcome. Cochrane Database of Syst Rev. 2017;17:CD004735.
    1. Sweet D, Bevilacqua G, Carnielli V, Greisen G, Plavka R, Saugstad OD, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome. J Perinat Med. 2017;35(3):175–186.
    1. Aidan G. O'Keeffe, Gareth Ambler and Julie A. Barber (2017): Sample size calculations based on a difference in medians positively skewed outcomes in health care studies. O'Keeffe et al. BMC Medical Research Methodology (2017) 17:157. DOI 10.1186/s12874-017-0426-1
    1. Navathe R, Schoen CN, Heidari P, et al. Azithromycin vs Erythromycin for the management of preterm premature rupture of membranes. Am J Obstet Gynecol. 2019;221:1–8. doi: 10.1016/j.ajog.2019.03.009.
    1. Gelber S, Brent E, Varrey A, Fridman B, Sapra K, Frayer W. Equivalence of Erythromycin and Azithromycin for treatment of PPROM. Am J Obstet Gynecol. 2013;208:291. doi: 10.1016/j.ajog.2012.10.028.
    1. Esteves JS, de Sá RA, de Carvalho PR, Coca Velarde LG. Neonatal outcome in women with preterm premature rupture of membranes (PPROM) between 18 and 26 weeks. J Matern Fetal Neonatal Med. 2016;29(7):1108–1112. doi: 10.3109/14767058.2015.1035643.
    1. Martingano D, Singh S, Mitrofanova A. Azithromycin in the treatment of preterm prelabor rupture of membranes demonstrates a lower risk of chorioamnionitis and postpartum endometritis with an equivalent latency period compared with erythromycin antibiotic regimens. Infect Dis Obstet Gynecol. 2020;2020:2093530. doi: 10.1155/2020/2093530.
    1. Sinrat N. The outcomes of ampicillin plus Azithromycin to prolong latency period in preterm premature rupture of membranes between 24 and 33+6 weeks of gestation at King Chulalongkorn Memorial Hospital. Thai J Obstet Gynaecol. 2020;28:175–182.
    1. Kole-White MB, Nelson LA, Lord M, et al. Pregnancy latency after preterm premature rupture of membranes: oral versus intravenous antibiotics. Am J Obstet Gynecol MFM. 2021;3(3):100333. 10.1016/j.ajogmf.2021.100333.
    1. Davis JM, Krew MA, Gill P, Nelson KM, Hopkins MP. The role of continuous fetal monitoring in the management of preterm premature rupture of membranes. J Matern Fetal Neonatal Med. 2008;21:301–304. doi: 10.1080/14767050802022789.
    1. Atarjavdan L, Khazaeipour Z, Shahbazi F. Correlation of myometrial thickness and the latency interval of women with preterm premature rupture of the membranes. Arch Gynecol Obstet. 2011;284:1339–1343. doi: 10.1007/s00404-011-1841-x.
    1. Phupong V, Kulmala L. Factors associated with latency period in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med. 2016;29(16):2650–2653.
    1. Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Combination of tocolytic agents for inhibiting preterm labour. Cochrane Database Syst Rev. 2014;(7):CD006169. 10.1002/14651858.CD006169.pub2.
    1. Labs P. Zithromax (R) highlights of prescribing information. 2013. Available at: . Accessed Sept. 17, 2018.
    1. Schreiber H, et al. Macrolide antibiotics roxithromycin vs. azithromycin for preterm premature rupture of membranes: a retrospective comparison. Arch Gynecol Obstet. 2019;300(3):569–573. doi: 10.1007/s00404-019-05221-w.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa